Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Ways You Can Help  
Share this page with someone you care about
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the appropriate link below.

Alzheimer's Disease Research
Macular Degeneration Research
National Glaucoma Research

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.

 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research - Current Award

Dr. Luciano Domenici

Luciano Domenici, M.D., Ph.D.

National Council of Research (C.N.R.)
Pisa, Italy

Title: RAGE, MAP kinases and Abeta induced synaptic dysfunction
Non-Technical Title: Role of RAGE in Alzheimer's disease

Duration: April 1, 2008 - March 31, 2010
Award Type: Pilot
Award Amount: $148,000


Summary:

Nerve signaling dysfunctions triggered by ABeta are central to AD progression. This study will lead to a better understanding of these processes, in particular, RAGE signaling. Results of this study will facilitate design of therapeutic agents that prevent or minimize the actions of ABeta on nerve signaling.

Details:

Alzheimer's disease (AD) is one of the main form of progressive neurodegenerative disorders leading to cognitive impairment with dementia. A typical feature of AD is the presence of beta amyloid (Aß) deposits in the form of plaques in different brain areas. Recent studies have higlighted the apparent discrepancy between neuropathological findings and cognitive impairment such as memory loss in AD. In the present project we raise the hypothesis that impairment of memory and neuronal dysfunction during an early phase of AD is due to oligomeric Aß, i.e. a step before the formation of plaques. In particular, for the first time, we aim to demonstrate that oligomeric Aß induces a nerve dysfunction in the entorhinal cortex, one of the brain areas affected in AD. The project will use a combination of electrophysiological and molecular approaches to show the mechanisms underlying oligomeric Aß induced neuronal dysfunction including the identification of receptors mediating Aß dysfunction. The outcome of these studies will be important to clarify the role of Aß and its receptors in different temporal phases of cortical neurodegenerative processes in AD. Deciphering new molecular aspects in AD pathology will be essential to define new therapeutical strategies leading to halt the progress of disease.